CTOs on the Move


 
Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on collaborating with companies in Health, Food, Energy, Environment, and Consumer Sectors to create biologically-based products that improve the quality of life and the health of the planet. Through the company’s proprietary UltraVector® platform and and suite of technologies, Intrexon provides its partners with industrial-scale design and development of complex biological systems. The UltraVector® platform delivers unprecedented control over the quality, function, and performance of living cells. We call our synthetic biology approach and integrated technologies Better DNA®, and we invite you to discover more at www.DNA.com.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.actogenix.com
  • 20358 Seneca Meadows Pkwy
    Germantown, MD USA 20876
  • Phone: 301.556.9900

Executives

Name Title Contact Details

Funding

Intrexon raised $200M on 08/22/2015

Similar Companies

American Addiction Centers

Why American Addiction Centers? We take a big picture approach to addiction recovery treatment – addressing the individual`s whole lifestyle in relation to substance use, alcohol and binge eating addiction and partnering with the family throughout the treatment process whenever possible. With our research-based programs, our inpatient treatment centers don`t just focus on the problem; we strengthen the individual and focus on the future. Whether it`s the initial clinical assessments, medically supervised detox, residential rehabilitation or aftercare, our team is present for and committed to each step of the recovery process for every individual. American Addiction Centers is an equal opportunity and drug free employer. All decisions regarding recruiting and hiring will be made without unlawful discrimination on the basis of race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, or age.

Ovid Therapeutics

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.

Wellbeats

Wellbeats gives people of every age, interest, body type, & ability level the same opportunity to live a healthier life.

Catholic Health

Our commitment is well-established, so we decided to shorten our name. Catholic Health Services of Long Island is now Catholic Health.

BioMedica Diagnostics

BioMedica Diagnostics Inc. is a Windsor, NS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.